The evaluation of the expression of ER, PR, and HER2 is a routine procedure in clinical practice, and it is essential for the determination of these subtypes, and so to guide hormonal and anti-HER2 treatments, additional to predict the prognosis of patients with BC [12]. This evidence concerns the gene PGR and breast cancer.